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APLF is a novel protein of unknown function that accumulates at sites of chromosomal DNA strand
breakage via forkhead-associated (FHA) domain-mediated interactions with XRCC1 and XRCC4. APLF can
also accumulate at sites of chromosomal DNA strand breaks independently of the FHA domain via an
unidentified mechanism that requires a highly conserved C-terminal tandem zinc finger domain. Here, we show
that the zinc finger domain binds tightly to poly(ADP-ribose), a polymeric posttranslational modification
synthesized transiently at sites of chromosomal damage to accelerate DNA strand break repair reactions.
Protein poly(ADP-ribosyl)ation is tightly regulated and defects in either its synthesis or degradation slow
global rates of chromosomal single-strand break repair. Interestingly, APLF negatively affects poly(ADP-
ribosyl)ation in vitro, and this activity is dependent on its capacity to bind the polymer. In addition, transient
overexpression in human A549 cells of full-length APLF or a C-terminal fragment encoding the tandem zinc
finger domain greatly suppresses the appearance of poly(ADP-ribose), in a zinc finger-dependent manner. We
conclude that APLF can accumulate at sites of chromosomal damage via zinc finger-mediated binding to
poly(ADP-ribose) and is a novel component of poly(ADP-ribose) signaling in mammalian cells.
The rapid repair of chromosomal DNA single- and double-
strand breaks is critical for genome integrity, and defects in this
process result in a variety of hereditary genetic diseases (21).
Recently, we and others identified the human protein APLF
(aka C2orf13, PALF, and XIP1) as a novel component of the
DNA single-strand break repair (SSBR) and double-strand
break repair (DSBR) machinery (4, 14, 15, 19). The amino
terminus of APLF contains a highly conserved forkhead-asso-
ciated (FHA) domain that mediates interaction with the SSBR
and DSBR factors XRCC1 and XRCC4, respectively. In addi-
tion, APLF interacts with Ku80 in an FHA domain-indepen-
dent manner. The C terminus of APLF contains a second
highly conserved region that encodes two tandem zinc fingers
(designated ZNF1 and ZNF2) and a highly acidic tail. Both the
FHA domain and the tandem ZNFs can facilitate, by indepen-
dent mechanisms, the accumulation of APLF at sites of DNA
strand breakage (4, 14, 15). Whereas the FHA domain facili-
tates APLF accumulation via interaction with CK2-phosphor-
ylated XRCC1, the mechanism by which the ZNFs achieve this
is unclear.
The ZNFs in APLF most closely resemble the tandem zinc
fingers present in tristetraprolin. Tristetraprolin binds specific
mRNA species, with each of two ZNFs targeting a separate
5-UAUU-3 subsite located within a larger, AU-rich recogni-
tion sequence (5, 18). Although APLF does not bind this
mRNA species (unpublished observations), it is possible that
the APLF ZNFs might interact with some other type of ade-
nine-rich structure. One such structure that arises during DNA
strand break repair is poly(ADP-ribose) (pADPr), a branched
nucleic acid-like polymer synthesized rapidly at DNA strand
breaks by pADPr polymerase-1 (PARP-1) and linked co-
valently to specific protein acceptors to signal the presence of
chromosome damage (reviewed in references 6 and 17). Pro-
tein poly(ADP-ribosyl)ation can affect protein function in a
variety of ways, such as by regulating the enzymatic activity of
its protein acceptor and/or by facilitating ionic interactions
with other proteins. The major targets of poly(ADP-ribosyl)-
ation at chromosomal DNA strand breaks are histone H1,
histone H2B, and PARP-1 itself. The poly(ADP-ribosyl)ation
of these proteins at chromosomal DNA breaks appears to
regulate chromatin structure and compaction and, also, the
accumulation of DNA repair protein complexes at sites of
chromosome damage (30–32). Importantly, both pADPr syn-
thesis and its subsequent catabolism by pADPr glycohydrolase
(PARG) (reviewed in reference 11) are critical for rapid rates
of chromosomal SSBR, indicating that the control of pADPr
levels at sites of DNA strand breakage is a dynamic and reg-
ulated process (10, 12). Here, we show that APLF binds tightly
to pADPr via its tandem zinc finger domain and that this
binding can suppress protein poly(ADP-ribosyl)ation in vitro
and in cells. These data provide a mechanism for the zinc
finger-dependent recruitment of APLF to chromosome dam-
age and suggest that APLF is a novel component of pADPr
signaling/metabolism in mammalian cells.
MATERIALS AND METHODS
Expression constructs. pET16b-APLF encoding full-length His-APLF has
been described previously (14). pET16b encoding His-APLF360–511, His-
APLF360-511zfm1 (harboring a mutated ZNF1 domain), and APLF360–511 zfm2
(harboring a mutated ZNF2 domain) were created by subcloning the 0.4-kb
SphI/BamHI fragment from the construct pEYFP-C1-APLF, pEYFP-C1-
APLFzfm1, or pEYFP-C1-APLFzfm2 (14), respectively, into NdeI (blunted)/
BamHI sites of pET16b. The mutations introduced into the ZNF1 and ZNF2
domains were C379A/C385A (ZNF1) and C421A/C427A (ZNF2). pET16b-
APLF1–469 was created by subcloning an NdeI/XbaI (blunted) restriction frag-
ment from pET16b-APLF into the NdeI/BamHI (blunted) sites of pET16b. The
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small interfering RNA targeting-resistant (TR) His-Myc-APLF expression con-
struct pcD2E-His-Myc-APLFTR was generated by site-directed mutagenesis
(Quickchange; Stratagene) of pcD2E-His-Myc-APLF (14) using appropriate oli-
gonucleotides (5-GAAAAGAAGAAATCTGTAAGGACAAATCCCAGCTA
AAC-3 and 5-GTTTAGCTGGGATTTGTCCTTACAGATTTCTTCTTTTC-
3) to introduce three silent mutations (underlined). The targeting-resistant open
reading frame was then subcloned from pcD2E-His-Myc-APLFTR into the
EcoR1 sites of pCI-puro, creating the puromycin-selectable construct pCI-puro-
His-Myc-APLFTR. C379/C385 and C421/C427 were each then changed to ala-
nine in pCI-puro-His-Myc-APLFTR by site-directed mutagenesis, creating
targeting-resistant expression constructs for His-Myc-APLFzfm1 and His-Myc-
APLFzfm2, respectively. A targeting-resistant expression construct for His-Myc-
APLF1–469 was generated by subcloning a 1.4-kb EcoRI/XbaI restriction frag-
ment from pCI-puro-His-Myc-APLFTR into the EcoRI/XbaI sites of pCI-puro.
pCI-puro-APLF360–511 was generated by subcloning an NcoI (blunted)/BamHI
(blunted) fragment from pET16b-APLF360–511 (14) into the NheI (blunted) site
of pCI-puro. The truncation in APLF360–511 renders this protein targeting resis-
tant.
Proteins. Histidine-tagged XRCC1 and APLF proteins were expressed from
pET16b constructs in Escherichia coli BL21(DE3) cells and purified by immobi-
lized-metal chelate chromatography and, for some experiments, gel filtration.
Recombinant human PARP-1 and PARG were purchased from Trevigen or,
where indicated in the case of PARP-1, expressed in insect cells (13) and purified
on 3-aminobenzamide-conjugated ECH Sepharose 4B as previously described
(The PARP Link Web resource [http://parplink.u-strasbg.fr/protocols/tools/parp
_purification.html]). Calf thymus histone H1 (mixed isoforms) was from Sigma,
and recombinant human histone H1.2 was from Axxora. Recombinant human
histone H2B was from New England Biolabs.
A549 transfection. A549 cell lines stably transfected with pSUPER-APLF,
designated A549-APLFKD (14), were maintained in minimal essential medium
supplemented with 15% fetal calf serum, 1.5 mg/ml G418, 2 mM L-glutamine, 50
U/ml penicillin, and 50 g/ml streptomycin. For subsequent transient transfec-
tions, A549-APLFKD cells were seeded onto coverslips (1  104 per cm2) and,
48 h later, transfected with the pCI-puro construct encoding the APLF proteins
indicated in Fig. 5 using GeneJuice (Novagen) according to the manufacturer’s
instructions. Twenty-four hours after transfection, the transfected cells were
treated with H2O2 and examined by immunofluorescence as described below.
Immunofluorescence. For laser-induced UVA damage, wild-type A549 cells or
A549-PARP-1KD cells stably depleted of PARP-1 (10) were seeded onto gridded
coverslips (MatTek). After preincubation for 10 min with 10 g/ml Hoechst dye
33258 at 37°C, selected cells were irradiated by using a 351-nm UVA laser
(approximately 0.35 J/m2). Where indicated (see Fig. 1A), cells were preincu-
bated with the PARP inhibitor KU58948 (500 nM). After exposure, coverslips
were incubated at 37°C for 4 min and washed in ice-cold phosphate-buffered
saline (PBS). For H2O2 treatment, cells were treated with 10 mM H2O2 in PBS
on ice for 20 min, rinsed in PBS, and incubated for 1 min in drug-free medium
at 37°C. Following DNA damage and repair incubation, all cells were rinsed in
ice-cold PBS and fixed in PBS–4% paraformaldehyde (5 min at room tempera-
ture), followed by methanol (20 min at 20°C). Cells were then permeabilized
with PBS–1% Triton X-100 (5 min), blocked in PBS–5% nonfat dried milk
(NFDM) for 30 min, and incubated in 1% NFDM–PBS-TS (0.1% Tween-20,
0.02% sodium dodecyl sulfate [SDS] in PBS) containing anti-pADPr monoclonal
antibody (MAb) (10H; Alexis) and anti-APLF polyclonal antibody (SK3595 [14])
at 1/200 dilution for 2 h at room temperature. After being rinsed (three times)
with PBS-TS, cells were incubated in Alexa Fluor 488 goat anti-mouse immu-
noglobulin G and Alexa Fluor 555 anti-rabbit immunoglobulin G (Invitrogen) at
1/200 dilution in 1% NFDM–PBS-TS for 1 h at room temperature. Cells were
then rinsed in PBS-TS (five times) and mounted in Vectashield (Vector Labo-
ratories).
Slot blot analysis of His-APLF binding to free pADPr and poly(ADP-ribosyl)-
ated proteins in vitro. Different amounts of pADPr (Trevigen) were slot blotted
onto Hybond-N (Amersham Bioscience) under vacuum and cross-linked with
UV. For the analysis of poly(ADP-ribosyl)ated proteins, 1 g of each of the
proteins indicated in Fig. 2A was slot blotted onto Hybond C-extra membrane
(Amersham Bioscience) and blocked in 5% NFDM, and filter-bound proteins
mock ribosylated or poly(ADP-ribosyl)ated with 4 U/ml recombinant human
PARP-1 (Trevigen) in PARP buffer (25 mM Tris, pH 8, 10 mM MgCl2, 100 mM
NaCl, 0.5 mM dithiothreitol), 340 M NAD (absent from mock ribosylation
reactions), and 4 g/ml of activated DNA. Membranes were blocked in binding
buffer (PBS plus 0.05% Tween 20) containing 5% NFDM for 30 min, washed,
and incubated in binding buffer in the presence or absence of 88 nM His-APLF
for 30 min at room temperature. APLF and pADPr were detected with anti-His
tag (Sigma) and anti-pADPr (10H) MAb, respectively.
Colorimetric analysis of His-APLF binding to poly(ADP-ribosyl)ated pro-
teins. Multiwell dishes coated with unfractionated calf thymus histone H1 (Trevi-
gen) were either mock treated or poly(ADP-ribosyl)ated with recombinant
PARP enzyme as recommended by the manufacturer (Trevigen). After being
rinsed (four times with PBS–0.1% Triton X-100), wells were blocked in PBS–
0.05% Tween 20–5% bovine serum albumin (BSA) for 30 min on ice and rinsed
four times with PBS–0.05% Tween 20. The wells were then either incubated or
not as indicated with wild-type or mutant APLF protein for 30 min on ice (unless
otherwise indicated). His-APLF was detected with anti-His-tag MAb (Sigma) (30
min on ice) followed by anti-mouse horseradish peroxidase (HRP)-conjugated
secondary antibody (30 min on ice). pADPr was detected with anti-pADPr MAb
(10H), followed by the secondary antibody described above. Rinsed immuno-
complexes were detected colorimetrically by incubation with the HRP substrate
TACS-Sapphire (Trevigen) as directed by the manufacturer.
Polyacrylamide gel electrophoresis (PAGE) analysis of His-APLF binding and
PARG activity on pADPr-histone H1.2 and pADPr-PARP-1. Flat-bottomed, 96-
well polystyrene plates (Greiner) were incubated with 0.1 mg/ml recombinant
human H1.2 (Axxora) or recombinant human PARP-1 (Trevigen) in PBS over-
night at 4°C. Bound histone was then poly(ADP-ribosyl)ated in the presence of
4 g/ml activated DNA (Trevigen), 4 U/ml recombinant human PARP-1 (Trevi-
gen), and 100 nM 32P-NAD (GE Healthcare) for 1 h at room temperature. The
wells containing pADPr-H1.2 were then rinsed and incubated in the absence or
presence of the indicated amounts of APLF (see Fig. 3) in 20 mM potassium
phosphate (pH 7.2), 50 mM KCl, 0.1 mg/ml BSA, 0.1% Triton X-100 (PARG
buffer; Trevigen) at 30°C or 15 min. The wells were then washed and incubated
with 10 ng/ml human PARG (Trevigen) for 15 min, after which released material
was collected. Released and residually bound materials were incubated with 2.5
mg/ml trypsin for 30 min at room temperature to cleave the ester linkage
between pADPr and protein acceptor, and equivalent aliquots of each fraction
separated on polyacrylamide sequencing gels (20% in Tris-borate-EDTA) and
detected by phosphorimager.
Analysis of His-APLF activity on ribosylated histone H1.2. Histone-coated
polystyrene plates were prepared as described above. The histones were ribosy-
lated for 30 min at room temperature in the presence of 68 M cold NAD, 40
nM 32P-NAD, 2 g/ml activated DNA, and 4 U/ml recombinant human
PARP-1. After being rinsed, the ribosylated histones were incubated in 2 g/ml
recombinant His-APLF or mutated His-APLF at 30°C for the times indicated in
the figures, after which the released material was collected. After trypsination of
the bound fraction, bound and released materials were quantified by phosphor-
imaging.
Analysis of PARP-1 autoribosylation. All reactions were carried out in PARP
buffer containing 20 U/ml (0.6 g/ml) recombinant human PARP-1 in the pres-
ence of 68 M cold NAD, 40 nM 32P-NAD, and 4 g/ml activated DNA. The
His-APLF protein indicated in the figures (88 nM), His-XRCC1 (88 nM), or 5
g/ml BSA (negative control) was added to the reaction mixture. After incu-
bation at 30°C for the indicated time, the reaction was stopped by 1 h
incubation on ice in acid loading buffer (30 mM phosphoric acid-Tris, pH 6,
4.5 M urea, 0.2% SDS, 5 mM dithiothreitol, 0.1% bromophenol blue) to
stabilize the pADPr-protein ester link. Samples were then subjected to acid
PAGE analysis (7.5% in 30 mM phosphoric acid-Tris, pH 6, 0.1% SDS) and
quantification by phosphorimaging.
RESULTS
Yellow fluorescent protein- or green fluorescent protein-
tagged APLF can accumulate at sites of chromosomal break-
age by a mechanism that is dependent on a highly conserved
C-terminal tandem zinc finger motif (4, 14, 15). Given the
similarity between the tandem zinc finger domain of APLF and
that of tristetraprolin, which binds an adenine-rich RNA motif,
we examined the relationship between endogenous APLF and
sites of pADPr synthesis following laser-induced UVA dam-
age. Both APLF and its interacting protein XRCC1 rapidly
accumulated at sites of UVA damage in human A549 cells and
did so in a manner that was dependent on the presence and
activity of PARP-1 (Fig. 1A). Moreover, the sites of UVA laser
damage and APLF accumulation were associated with high
levels of PARP-1-dependent pADPr synthesis (Fig. 1B). These
data confirm that endogenous APLF accumulates at sites of
VOL. 28, 2008 APLF AND POLY(ADP-RIBOSE) SIGNALING 4621
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pADPr synthesis, in a PARP-1 dependent manner, and are
consistent with a functional relationship between APLF and
pADPr.
Next, we employed slot blot analyses to determine
whether APLF interacts with pADPr. Full-length recombi-
nant human His-APLF bound to nitrocellulose filter in a
manner that was dependent on the amount of slot-blotted
polymer (Fig. 1C). Because cellular pADPr is a protein
posttranslational modification, we also examined whether
His-APLF interacted with poly(ADP-ribosyl)ated proteins.
FIG. 1. APLF colocalizes with and binds pADPr. (A) Human A549 cells, A549 cells stably depleted of PARP-1 (A549-PARP-1KD) (10), or
A549 cells incubated with PARP inhibitor (A549  Parp Inhib.) were damaged by UVA laser in the indicated area (dashed rectangle) and, 4 min
later, fixed and immunostained with anti-APLF or anti-XRCC1 MAb. Nuclear DNA was counterstained with 4,6-diamidino-2-phenylindole
(DAPI). Representative images are shown. (B) Human A549 cells or A549 cells stably depleted of PARP-1 (A549-PARP-1KD) (10) were damaged
by UVA laser, and 4 min later, fixed and immunostained with anti-APLF and anti-pADPr MAb. Other details are as described for panel A. (C) The
indicated amounts of pADPr were slot blotted, and the filters incubated in the presence or absence of His-APLF (88 nM). Washed filters were
then incubated with anti-His-tag or anti-pADPr MAb antibodies as indicated. (D) Multiwell dishes coated with calf thymus histone H1 (mixed
isoforms) were mock ribosylated (h1 and ) or poly(ADP-ribosyl)ated (pADPr-h1) and, after being washed, quantified for levels of immobilized
pADPr (right) or incubated with the indicated amounts of recombinant full-length His-APLF for 30 min on ice (left). Immobilized His-APLF or
pADPr was detected with anti-His-tag (left) or anti-pADPr primary antibody (right), followed by anti-HRP-conjugated secondary antibody, and
quantified colorimetrically (450 nm). Where indicated (), histone-coated wells were pretreated with trypsin to remove all protein prior to
poly(ADP-ribosyl)ation. Error bars show standard errors of the mean. , anti; , present; , absent.
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Indeed, His-APLF bound much more efficiently to dishes
coated with poly(ADP-ribosyl)-ated histone H1 (pADPr-
H1) than to unmodified histone H1-coated dishes (Fig. 1D).
To identify the region(s) of APLF responsible for pADPr
binding, we employed a number of mutated derivatives lack-
ing or mutated in specific domains (Fig. 2A). A C-terminal
fragment of His-APLF (His-APLF360–511) containing the
highly conserved tandem ZNFs and acidic tail bound effi-
ciently to pADPr-H1, but an amino-terminal fragment en-
coding the FHA domain (His-APLF1–166) did not (Fig. 2B).
Whereas deletion of the acidic C-terminal tail (His-APLF1–469)
did not affect binding to pADPr-H1, mutation of the ZNF1
domain (His-APLF360-511zfm1) greatly reduced or ablated it
(Fig. 2B). Mutation of ZNF2 (His-APLF360-511zfm2) did not
reduce pADPr-H1 binding under the same conditions, but did
reduce binding by approximately half at physiological temper-
ature (Fig. 2C, left panel). Binding by His-APLF360-511zfm2 may
thus be temperature sensitive. His-APLF also bound poly-
(ADP-ribosyl)ated histone H2B and PARP-1, indicating that
binding is not restricted to poly(ADP-ribosyl)ated histone H1
FIG. 2. The tandem zinc finger domain of APLF binds poly(ADP-ribosyl)ated proteins in vitro. (A) Recombinant human His-APLF proteins.
One microgram of recombinant His-APLF and the indicated mutated derivatives were fractionated by SDS-PAGE and stained with Coomassie
blue. A schematic of the recombinant His-APLF proteins is shown (bottom). “H-” and “FHA” denote the decahistidine tag and FHA domain,
respectively. The C-terminal acidic tail (gray box) and tandem ZNF domains (black boxes: , ZNF1; , ZNF2) are also indicated. Dotted boxes
denote a mutated ZNF. Amino acid positions are indicated at the top. (B) Multiwell dishes coated with calf thymus histone H1 were poly(ADP-
ribosyl)ated (pADPr-h1) or not (h1) as described above and incubated in the absence () or presence of 17.5 nM of the indicated His-APLF
protein for 30 min on ice. Bound His-APLF was quantified as described above. (C) Multiwell dishes coated with calf thymus histone H1 were
poly(ADP-ribosyl)ated and incubated with the indicated concentration of the indicated His-APLF protein for 30 min at 37°C. Bound His-APLF
was quantified as described above. (D) Two micrograms of BSA, calf thymus histone H1, recombinant human histone H2B, or recombinant human
PARP-1 was slot blotted onto nitrocellulose and mock treated (pADPr) or poly(ADP-ribosyl)ated (pADPr) with recombinant human PARP-1
(P1). Filters were incubated with 35 nM His-APLF, and after extensive washing, filter-bound APLF was detected with anti-His-Tag MAb and
appropriate secondary antibody. Error bars show standard errors of the mean.
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(Fig. 2D). We conclude that APLF binds to pADPr and to
poly(ADP-ribosyl)ated proteins and that this activity is medi-
ated by the tandem ZNFs.
To examine His-APLF binding to pADPr-H1 in more detail,
we examined the impact of this protein on the sensitivity of
pADPr to PARG, the cellular enzyme that catabolizes pADPr
(7, 33). For this purpose, we employed multiwell dishes coated
with [32P]poly(ADP-ribosyl)ated recombinant human histone
H1.2 (pADPr-H1.2). Incubation with PARG released almost
all pADPr from histone H1 as mono(ADP-ribose) (mADPr)
within 30 min, consistent with the robust exoglycosidic activity
of this protein (Fig. 3A, lanes 1 and 4). In contrast, preincu-
bation of pADPr-H1.2 with 17.5 nM His-APLF resulted in the
appearance of a PARG-resistant “footprint” of1 to 20 ADPr
units in the residual histone H1-bound material (Fig. 3A, lane
5). This suggests that His-APLF binds tightly to pADPr-H1.2,
close to the junction between pADPr and histone. Similar
results were observed with 10-fold-higher concentrations of
His-APLF, although in this case the footprint was larger and
thus extended further from the polymer-histone junction (Fig.
3A, lane 6). A small amount of protected pADPr was also
present in the released material (see Fig. 3A, lanes 2 and 3),
which contains polymer released “spontaneously” due to the
intrinsic instability of some of the ester bonds linking pADPr
to the protein acceptor (22–24, 26). Similar results were ob-
served for poly(ADP-ribosyl)ated PARP-1, suggesting that
His-APLF also binds tightly to pADPr-PARP-1 (Fig. 3B).
The ability to bind tightly to pADPr provides a mechanism
for the ZNF-dependent accumulation of APLF into sub-
nuclear foci at sites of chromosomal DNA strand breakage (4,
14, 15). However, we wondered whether interaction with
pADPr may also impact on pADPr metabolism, especially
since we noticed in experiments similar to those described
above, but in described above which we omitted PARG, that
incubation with His-APLF increased the amount of pADPr
released from histone H1.2 (data not shown). Quantitative
analysis revealed that both His-APLF and His-APLF360–511
increased pADPr release threefold above the amount re-
leased spontaneously and that this was dependent on an intact
ZNF1 domain (Fig. 4A and B). Separation of the reaction
products on a sequencing gel revealed that the pADPr released
by APLF was comprised of branched and linear polymers of all
sizes, similar to that released “spontaneously,” suggesting that
APLF binding decreased the stability of some of the labile
ester linkages between pADPr and histone H1.2 (Fig. 4C). In
contrast to histone H1.2, His-APLF did not measurably pro-
mote the release of pADPr from autoribosylated PARP-1
(data not shown).
We also considered the possibility that APLF binding might
affect pADPr synthesis, since negative regulation of pADPr
synthesis by PARP-1 has been reported for XRCC1, which also
binds to pADPr (20, 29). Notably, full-length His-APLF
slowed the rate of PARP-1 autoribosylation in vitro to an
extent similar to that observed with the protein XRCC1 (Fig.
4D, left panel). The His-APLF360–511 protein, containing the
highly conserved tandem ZNFs and acidic tail, also slowed the
rate of PARP-1 autoribosylation, whereas His-APLF1–166, en-
coding just the FHA domain, did not. As observed for pADPr
binding, deletion of the acidic C-terminal tail (His-APLF1-469)
did not affect the impact of APLF on pADPr synthesis (Fig.
4D, left panel), whereas mutation of the ZNF1 domain (His-
APLF360-511zfm1) greatly reduced or ablated it (Fig. 4D, right
panel). Mutation of the ZNF2 domain, which under the con-
ditions employed does not measurably affect pADPr binding,
had little or no impact on the ability of APLF to inhibit pADPr
synthesis. We thus conclude that APLF binding can affect the
rate of pADPr synthesis in vitro.
We next examined whether His-APLF might affect cellular
pADPr metabolism by examining the effect of transiently ex-
pressing targeting-resistant derivatives of His-Myc-APLF pro-
tein in A549 cells stably depleted of APLF (A549-APLFKD)
(14). Surprisingly, transient overexpression of targeting-resis-
tant full-length protein (His-Myc-APLFTR) in A549-APLFKD
cells greatly reduced or ablated the appearance of pADPr,
even at very early times (1 min) after H2O2 treatment (Fig. 5A,
FIG. 3. APLF binding protects pADPr from degradation by
PARG. (A) Multiwell dishes coated with recombinant human histone
H1.2 were poly(ADP-ribosyl)ated in the presence of 32P-NAD and
incubated with 0 nM (lanes 1, 4, and 7), 1.75 nM (lanes 2, 5, and 8), or
17.5 nM (lanes 3, 6, and 9) of His-APLF for 15 min. The histone
H1.2-coated dishes were then incubated in the presence () or ab-
sence () of PARG protein for 15 min. Released and bound materials
were analyzed by native PAGE and detected by phosphorimager. The
position of mADPr (“n”), pADPr of two or more ADPr units (2n, 3n,
and 4n, etc.), and branched pADPr molecules remaining at the origin
(16, 27) are indicated. (B) Multiwell dishes were coated with recom-
binant human PARP-1 (purified from insect cells). Other details are as
described for panel (A).
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top panels, and B). To examine whether the suppression of
pADPr signaling by APLF involved polymer binding, we ex-
amined whether the ZNFs were sufficient and/or required for
this effect. Indeed, the overexpression of APLF360-511, encod-
ing just the C-terminal tandem ZNFs and acidic tail, was suf-
ficient for the suppression of pADPr following H2O2 treatment
(Fig. 5A, bottom panels, and B). Moreover, the overexpression
of His-Myc-APLF harboring a mutant of either ZNF1
(“zfm1”) or ZNF2 (“zfm2”) failed to suppress pADPr effi-
ciently, confirming the importance of the tandem ZNF domain
for this activity (Fig. 5A and B). We noted that deletion of the
acidic C-terminal tail (APLF1–469), which is dispensable for
FIG. 4. Impact of APLF on pADPr metabolism in vitro. (A) Release of [32P]pADPr from ribosylated histone H1.2 by APLF. Multiwell dishes
coated with recombinant human histone H1.2 were poly(ADP-ribosyl)ated in the presence of NAD that was spiked with 32P-NAD and then
washed and incubated with His-APLF (APLF) or buffer alone (APLF) for the times indicated at 30°C. Released material and bound material
were detected by phosphorimager, and the released material plotted as a percentage of total 32P signal (released plus bound) in each reaction
mixture. Inset shows a representative phosphorimage. (B) Release of [32P]pADPr from ribosylated histone H1.2 by the C-terminal domain of
APLF. Ribosylated histone H1.2 was incubated as described above with buffer alone, His-APLF360–511, His-APLF360-511zfm1, or His-APLF360-511zfm2
for the times indicated. Other details are as described for panel A. (C) Analysis by native PAGE of material generated in one of the experiment
whose results are shown in panel B. , buffer alone. (D) The results in the left panel show the impact of APLF on PARP-1 autoribosylation.
PARP-1 autoribosylation was conducted in the presence of NAD that was spiked with 32P-NAD, and 32P-labeled PARP-1 was quantified on
acid PAGE gels by phosphorimager. Reaction mixtures included BSA, His-APLF, His-APLF360–511, His-APLF1–166, His-APLF1–469, or His-
XRCC1. A representative phosphorimage showing PARP-1 ribosylation is included (inset). Data are plotted relative to the signal obtained after
15 min of incubation in the presence of BSA (negative control). The results in the right panel show the impact of the C-terminal domain of APLF
on PARP-1 autoribosylation. Reactions were conducted as described for the left panel, and the reaction mixtures included BSA, His-APLF360-511,
His-APLF360-511zfm1, or His-APLF360-511zfm2. Error bars show standard errors of the mean.
VOL. 28, 2008 APLF AND POLY(ADP-RIBOSE) SIGNALING 4625
 o
n
 June 19, 2014 by guest
http://m
cb.asm
.org/
D
ow
nloaded from
 
pADPr binding in vitro, also suppressed the effect of APLF on
pADPr accumulation after H2O2 treatment, suggesting that
while polymer binding is required for this purpose, it is not
sufficient (Fig. 5A and B).
In summary, we show that APLF binds tightly to pADPr via
its tandem zinc finger domain and that this binding can sup-
press protein poly(ADP-ribosyl)ation in vitro and in cells.
These data provide a mechanism for the zinc finger-dependent
recruitment of APLF to chromosome damage and suggest that
APLF is a novel component of pADPr signaling/metabolism in
mammalian cells.
DISCUSSION
APLF is comprised of highly conserved amino- and carboxyl-
terminal domains separated by a relatively nonconserved central
region and was recently identified as a novel component of
DNA SSBR and DSBR (4, 14, 15, 19). The amino-terminal
domain encodes an FHA domain that interacts with CK2-
phosphorylated XRCC1 and XRCC4 and facilitates the accu-
mulation of APLF at sites of chromosomal DNA damage in an
XRCC1-dependent manner. In addition, the accumulation of
APLF can occur independently of the FHA domain via a
mechanism that utilizes the C-terminal tandem zinc finger do-
main. The finding reported here that the tandem ZNFs inter-
act with pADPr provides a likely mechanism for the ZNF-
dependent accumulation of APLF at chromosome breaks.
Consistent with this idea, mutation of the ZNF1 domain ab-
lated both pADPr binding and APLF accumulation, whereas
mutation of the ZNF2 domain allowed residual levels of both
(Fig. 2C) (13). These data are in agreement with the results in
FIG. 5. Suppression of pADPr signaling by APLF overexpression. (A) A549-APLFKD cells were transiently transfected with expression
constructs encoding targeting-resistant His-Myc-APLF, His-Myc-APLF1–469, His-Myc-APLFzfm1, and APLF360–511, and 48 h later, treated with
H2O2 (20 min on ice) followed by 1 min in drug-free medium. Cells were then immunostained with anti-APLF (red) and anti-pADPr (green)
antibodies and analyzed by immunofluorescence microscopy. Transfected cells expressing detectable levels of recombinant APLF are highlighted
by white arrows. Cell nuclei were counterstained with 4,6-diamidino-2-phenylindole (DAPI; blue). Images are representative of multiple
experiments and were captured at 40 magnification. (B) The fraction of A549-APLFKD cells with detectable pADPr signal was quantified from
the APLF-expressing (red) subset of transiently transfected cells in panel A or from total populations of untransfected cells (). Data are the
means ( 1 standard error of the mean) of the results from three independent experiments.
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a recent report suggesting that the ability to bind free pADPr
polymer is a common function of the type of zinc finger present
in APLF and in several other proteins (3). In the current
experiments, APLF also bound polymer that was conjugated to
histone H1, histone H2B, and PARP-1 (Fig. 2D). This is im-
portant because cellular pADPr arises at sites of chromosomal
damage largely as a posttranslational modification of these
proteins rather than as free polymer.
It is possible that pADPr binding by APLF fulfils another
role in addition to targeting this protein to chromosomal DNA
strand breaks. Consistent with this idea, APLF overexpression
in APLF-depleted A549 cells reduced the steady-state level of
pADPr at early times following H2O2 treatment, in a zinc
finger-dependent manner, raising the possibility that APLF
might play a role in regulating cellular pADPr levels. Interest-
ingly, the highly conserved acidic C-terminal tail was also re-
quired for the ability of APLF to suppress cellular pADPr,
despite the dispensability of this domain for pADPr binding.
Consequently, while pADPr binding by APLF is most likely
required for the suppression of cellular pADPr, it is unlikely to
be sufficient for this activity. APLF promoted the release of up
to 30% of pADPr from histone H1.2 in vitro (Fig. 4A), sug-
gesting that polymer binding may destabilize some of the labile
ester linkages that connect pADPr to histone (1, 2, 24, 26). The
limited release of pADPr exhibited by His-APLF is reminis-
cent of the activity of mADPr lyase, an activity that cleaves a
subset of ester bonds linking mADPr to protein (24, 26). How-
ever, we failed to detect the release of significant amounts of
mADPr by APLF (unpublished observations). The limited ac-
tivity of APLF in vitro, and particularly the absence of activity
on PARP-1, which is the major poly(ADP-ribosyl)ated protein
in cells, suggests that pADPr release is unlikely to account for
the impact of APLF on cellular pADPr levels, at least by itself.
Another contributing factor may be the ability of APLF to
inhibit pADPr synthesis by PARP-1 that was observed in this
study. This activity was similarly dependent on an intact ZNF1
domain, suggesting that it too requires polymer binding. It is
possible that tight binding by APLF to nascent pADPr chains
affects access to the polymer terminus by PARP-1, thereby
negatively regulating polymer extension.
It remains to be determined whether or not regulating the
cellular levels of pADPr is a physiological role of APLF. How-
ever, such a role would be an important component of chro-
mosomal DNA strand break repair, because pADPr levels are
highly dynamic following DNA breakage and greatly affect the
accumulation and/or stability of DNA repair protein com-
plexes at chromosomal DNA strand breaks (9, 10, 25). This is
illustrated by the observation that depletion of PARP-1 and/or
PARG reduces global rates of SSBR to a similar extent (10). In
addition, the poly(ADP-ribosyl)ation of histones can relax
higher-order chromatin folding and facilitate histone shuttling
(8, 28, 30, 31), suggesting that the proper regulation of pADPr
levels may be critical for controlling chromatin structure dur-
ing cellular SSBR reactions.
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